基于16S rDNA探讨芎麻汤有效成分对偏头痛大鼠肠道微生物的影响OA
Exploring the effects of Xiongmatang active ingredients on gut microbiota in a rat migraine model based on 16S rDNA
目的 研究芎麻汤有效成分对偏头痛大鼠肠道微生物的影响.方法 120 只大鼠进行硬脑膜置管手术后,观察大鼠宏观体征,选取生活状态较好的90 只大鼠于12 d内6 次注射炎症汤刺激硬脑膜建立偏头痛模型,随机设置为 9 组,每组 10 只:模型组、降钙素基因相关肽(CGRP)抑制剂组、氟桂利嗪阳性组、芎麻汤有效成分组(芎麻汤正丁醇提取物低、高剂量组、芎麻汤乙酸乙酯提取物低、高剂量组、芎麻汤正丁醇+乙酸乙酯提取物低、高剂量组);另设置空白组10 只,以上述相同建模方法注射0.9%氯化钠溶液.模型建立后,空白组与模型组灌胃纯水,CGRP抑制剂组大鼠经尾静脉给药,每周1 次,共5 次;余组灌胃相应药物,每天1 次,共 4 周(28 d).给药末期,通过大鼠糖水偏爱度检测、悬尾测试、新物体识别测试、水迷宫测试进行行为学评估;腹主动脉采血、ELISA法检测大鼠外周血CGRP、NO含量;取肠道内容物,16S rDNA高通量测序技术分析大鼠肠道微生物变化.结果 与空白组相比,模型组大鼠表现出显著的抑郁样行为改变及认知障碍,同时血清中CGRP、NO含量明显升高(P<0.05).肠道菌群分析显示菌群结构发生明显变化,在门水平,厚壁菌门(Firmicutes)、放线菌门(Actinobacteriota)、Unclassified和弯曲杆菌门(Campylobacterota)群落丰度明显降低(P<0.01,P<0.05),拟杆菌门(Bacteroidota)、疣微菌门(Verrucomicrobiota)、髌骨细菌门(Patescibacteria)和蓝藻细菌门(Cyanobacteria)群落丰度明显升高(P<0.01,P<0.05);在属水平,Muribaculaceae_unclassified、乳酸杆菌(Lactobacillus)群落丰度明显降低(P<0.05),瘤胃球菌(Ruminococcus)、Clostridia_UCG-014_unclassified、阿克曼菌(Akkermansia)、Firmicutes_unclassified和Monoglobus群落丰度明显升高(P<0.01,P<0.05).与模型组相比,氟桂利嗪阳性组、CGRP抑制剂组、芎麻汤有效成分组均不同程度地明显改善偏头痛大鼠出现的抑郁样行为改变及认知障碍;均明显降低血清中CGRP、NO含量.芎麻汤有效成分组能够不同程度调节大鼠肠道微生物的多样性,α多样性分析提示其能提高大鼠肠道菌群多样性和丰富度(P<0.01,P<0.05),β多样性分析提示芎麻汤有效成分组大鼠的肠道微生物群落结构与空白组接近,且其肠道菌群结构在门、属水平上均观察到了与模型组相反的趋势.结论 芎麻汤有效成分可能通过调节偏头痛大鼠肠道微生物防治偏头痛.
Objective To study the effect of Xiongmatang active ingredients on intestinal microbes in a rat migraine model.Methods One hundred and twenty rats underwent dural cannulation surgery,and general physical signs were observed.Ninety healthy rats were selected and injected with inflammation soup six times within 12 days to stimulate the dura mater to create a migraine model.These rats were randomly divided into nine groups of 10 rats:model,calcitonin gene-related peptide(CGRP)inhibitor,flunarizine-positive(Flunarizine),and Xiongmatang active ingredients(low-and high-dose groups for n-butanol,ethyl acetate,and n-butanol+ethyl acetate extracts).An additional control group of 10 rats was established,injected with 0.9%sodium chloride solution using the same modeling procedure.After successful modeling,the control and model groups were given pure water by gavage,and the CGRP inhibitor group were given the drug by tail vein five times,once a week;the other groups were given corresponding doses,once a day,for a total of 4 weeks(28 d).Behavioral assessments were then conducted using sucrose preference,tail suspension,novel object recognition,and Morris water-maze tests.Abdominal aortic blood was collected for enzyme-linked immunosorbent assay quantification of circulating CGRP and NO levels.Intestinal contents were taken,and the changes in the gut microbiota were analyzed by 16S rDNA high-throughput sequencing.Results Compared with the control group,model group rats exhibited significant depressive-like behavioral changes and cognitive impairments,meanwhile,the contents of CGRP and NO in serum were significantly increased(P<0.05).Gut microbiota analysis revealed alterations in microbial community structure.At the phylum level,the abundance of Firmicutes,Actinobacteriota,Unclassified,and Campylobacterota decreased significantly(P<0.01,P<0.05),while that of Bacteroidota,Verrucomicrobiota,Patescibacteria,and Cyanobacteria increased significantly(P<0.01,P<0.05).At the genus level,abundances of certain genera,such as Muribaculaceae_unclassified and Lactobacillus,were significantly decreased(P<0.05),while Ruminococcus,Clostridia_UCG-014_unclassified,Akkermansia,Firmicutes_unclassified,and Monoglobus significantly increased(P<0.01,P<0.05).Compared with the model group,the CGRP inhibitor,Flunarizine group,and Xiongmatang active ingredients dose-dependently reversed these depressive-like behavioral changes and cognitive impairments,and significantly lowered serum levels of CGRP and NO.The active ingredients of Xiongmatang treatment also modulated intestinal microbial diversity;α-diversity assays showed increased richness and evenness,while β-diversity revealed that the microbial community structure of Xiongmatang-treated rats closely resembled that of the control group.At both phylum and genus levels,the alterations in microbiota composition exhibited trends opposite to those seen in the model group.Conclusions The active ingredients of Xiongmatang may prevent and treat migraines in rats through gut microbiota regulation.
何琪;常露露;刘顶鼎;曾贵荣;陈唯实;姜宁;刘冬;吴雪梅;吴远华
贵州中医药大学药学院/中药民族药药性研究中心,贵阳 550025贵州中医药大学药学院/中药民族药药性研究中心,贵阳 550025贵州中医药大学药学院/中药民族药药性研究中心,贵阳 550025湖南省药物安全评价研究中心/新药药效与安全性评价湖南省重点实验室,长沙 410331贵州中医药大学药学院/中药民族药药性研究中心,贵阳 550025中国医学科学院北京协和医学院药用植物研究所,北京 100193贵州中医药大学药学院/中药民族药药性研究中心,贵阳 550025贵州中医药大学第一附属医院,贵阳 550001贵州中医药大学第一附属医院,贵阳 550001
医药卫生
偏头痛芎麻汤有效成分肠道微生物16S rDNA降钙素基因相关肽
migraineactive ingredients of Xiongmatanggut microbes16S rDNACGRP
《中国比较医学杂志》 2026 (3)
19-35,17
国家自然科学基金项目(82160894,82460922)贵州省科学技术基金计划项目(黔科合基础-ZK[2024]一般375).
评论